Skip to content
2000
image of Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy

Abstract

Vagina is one of the crucial parts of the female reproductive system and is often afflicted by various diseases. Vulvovaginal candidiasis (VVC) is the most common disease caused by Candida species. VVC affects nearly 75% of women at least once in their lifetime and exhibits a high recurrence rate. Current first-line treatments for VVC include antifungal agents such as azoles, polyenes and echinocandins. Emerging therapies like herbal remedies, probiotics and immunotherapeutic vaccines are also available, with azoles being the most commonly used. While effective, these therapies are often limited by drawbacks, including resistance development, adverse effects and suboptimal therapeutic outcomes. Conventional forms of dosage, such as creams, tablets and intravenous infusions, have shown limited success in addressing the complexity of VVC, particularly biofilm formation, which impedes therapeutic efficacy. To overcome these challenges, novel drug delivery systems (NDDS) are being explored, including lipid-based carriers, inorganic nanocarriers, microneedles, nanofibers and gels, which offer enhanced drug delivery and improved bioavailability. Additionally, polymers used in vaginal drug delivery have shown potential in improving the stability and release profiles of formulations. In this review, a comprehensive overview of the pathophysiology and therapeutic strategies has been provided, along with recent advancements in novel drug delivery systems. It highlights their potential and ability to overcome current therapeutic challenges and pave the way for more effective and patient-friendly management of the condition.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128384805251014064906
2026-02-10
2026-02-24

  • From This Site

    /content/journals/cpd/10.2174/0113816128384805251014064906
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. de Cássia Orlandi Sardi J. Silva D.R. Anibal P.C. Vulvovaginal candidiasis: Epidemiology and risk factors, pathogenesis, resistance and new therapeutic options. Curr. Fungal Infect. Rep. 2021 15 1 32 40 10.1007/s12281‑021‑00415‑9
    [Google Scholar]
  2. Gonçalves B. Ferreira C. Alves C.T. Henriques M. Azeredo J. Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016 42 6 905 927 10.3109/1040841X.2015.1091805 26690853
    [Google Scholar]
  3. Behzadi P. Behzadi E. Ranjbar R. Urinary tract infections and Candida albicans. Cent. European J. Urol. 2015 68 1 96 101 25914847
    [Google Scholar]
  4. Neal C.M. Martens M.G. Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis. SAGE Open Med. 2022 10 20503121221115201 10.1177/20503121221115201 36105548
    [Google Scholar]
  5. Denning D.W. Kneale M. Sobel J.D. Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: A systematic review. Lancet Infect. Dis. 2018 18 11 e339 e347 10.1016/S1473‑3099(18)30103‑8 30078662
    [Google Scholar]
  6. Rodríguez-Cerdeira C. Gregorio M.C. Molares-Vila A. Biofilms and vulvovaginal candidiasis. Colloids Surf. B Biointerfaces 2019 174 110 125 10.1016/j.colsurfb.2018.11.011 30447520
    [Google Scholar]
  7. Díaz-Navarro M. Irigoyen-von-Sierakowski Á. Delcán I. New insights in the role of Candida biofilm in the pathogenesis of recurrent vulvovaginal candidiasis: A prospective clinical study. Front. Microbiol. 2025 16 1566171 10.3389/fmicb.2025.1566171 40212387
    [Google Scholar]
  8. Sawant B. Khan T. Recent advances in delivery of antifungal agents for therapeutic management of candidiasis. Biomed. Pharmacother. 2017 96 1478 1490 10.1016/j.biopha.2017.11.127 29223551
    [Google Scholar]
  9. Nagaraj S. Manivannan S. Narayan S. Potent antifungal agents and use of nanocarriers to improve delivery to the infected site: A systematic review. J. Basic Microbiol. 2021 61 10 849 873 10.1002/jobm.202100204 34351655
    [Google Scholar]
  10. Dalabehera M. Rathore C. Rathee A. Lal U.R. From plants to particles: herbal solutions and nanotechnology combating resistant vulvovaginal candidiasis. Ther. Deliv. 2024 15 5 371 392 10.4155/tde‑2023‑0133 38651887
    [Google Scholar]
  11. Negi P. Singh A. Pundir S. Essential oil and nanocarrier-based formulations approaches for vaginal candidiasis. Ther. Deliv. 2023 14 3 207 225 10.4155/tde‑2022‑0058 37191049
    [Google Scholar]
  12. Sadanov A. Antifungal therapy and probiotics in women’s health - A comprehensive review. Adv. Life Sci. 2024 11 4 927 942
    [Google Scholar]
  13. Akinosoglou K-A. Papageorgiou D. Gogos C. Dimopoulos G. An update on newer antifungals. Expert Rev. Anti Infect. Ther. 2025 23 2–4 149 158 10.1080/14787210.2025.2461566 39881622
    [Google Scholar]
  14. Iqbal Z. Dilnawaz F. Nanocarriers for vaginal drug delivery. Recent Pat. Drug Deliv. Formul. 2019 13 1 3 15 10.2174/1872211313666190215141507 30767755
    [Google Scholar]
  15. El-Hammadi M.M. Arias J.L. Nanomedicine for vaginal drug delivery. Theory and applications of Nonparenteral Nanomedicines. Elsevier 2021 235 257 10.1016/B978‑0‑12‑820466‑5.00011‑9
    [Google Scholar]
  16. Subi M.T.M. Selvasudha N. Vasanthi H.R. Vaginal drug delivery system: A promising route of drug administration for local and systemic diseases. Drug Discov. Today 2024 29 6 104012 10.1016/j.drudis.2024.104012 38705512
    [Google Scholar]
  17. Mahant S. Sharma A.K. Gandhi H. Wadhwa R. Dua K. Kapoor D.N. Emerging trends and potential prospects in vaginal drug delivery. Curr. Drug Deliv. 2023 20 6 730 751 10.2174/1567201819666220413131243 35422213
    [Google Scholar]
  18. Valamla B. Thakor P. Phuse R. Engineering drug delivery systems to overcome the vaginal mucosal barrier: Current understanding and research agenda of mucoadhesive formulations of vaginal delivery. J. Drug Deliv. Sci. Technol. 2022 70 103162 10.1016/j.jddst.2022.103162
    [Google Scholar]
  19. Pandey M. Choudhury H. Abdul-Aziz A. Promising drug delivery approaches to treat microbial infections in the vagina: A recent update. Polymers 2020 13 1 26 10.3390/polym13010026 33374756
    [Google Scholar]
  20. Wong T.W. Dhanawat M. Rathbone M.J. Vaginal drug delivery: Strategies and concerns in polymeric nanoparticle development. Expert Opin. Drug Deliv. 2014 11 9 1419 1434 10.1517/17425247.2014.924499 24960192
    [Google Scholar]
  21. Chindamo G. Sapino S. Peira E. Chirio D. Gallarate M. Recent advances in nanosystems and strategies for vaginal delivery of antimicrobials. Nanomaterials 2021 11 2 311 10.3390/nano11020311 33530510
    [Google Scholar]
  22. Hady M.A. Darwish A.B. Abdel-Aziz M.S. Sayed O.M. Design of transfersomal nanocarriers of nystatin for combating vulvovaginal candidiasis; A different prospective. Colloids Surf. B Biointerfaces 2022 211 112304 10.1016/j.colsurfb.2021.112304 34959094
    [Google Scholar]
  23. Hsin Y.K. Thangarajoo T. Choudhury H. Pandey M. Meng L.W. Gorain B. Stimuli-responsive in situ spray gel of miconazole nitrate for vaginal candidiasis. J. Pharm. Sci. 2023 112 2 562 572 10.1016/j.xphs.2022.09.002 36096286
    [Google Scholar]
  24. Johal H.S. Garg T. Rath G. Goyal A.K. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv. 2016 23 2 550 563 10.3109/10717544.2014.928760 24959937
    [Google Scholar]
  25. Vartak R. Menon S. Patki M. Liang X. Billack B. Patel K. Nanomedicine for the treatment of vaginal candidiasis. In: AAPS Advances in the Pharmaceutical Sciences Series. Cham Springer 2023 125 147 10.1007/978‑3‑031‑39020‑3_5
    [Google Scholar]
  26. Gupta P. Meher M.K. Tripathi S. Poluri K.M. Nanoformulations for dismantling fungal biofilms: The latest arsenals of antifungal therapy. Mol. Aspects Med. 2024 98 101290 10.1016/j.mam.2024.101290 38945048
    [Google Scholar]
  27. Akinosoglou K. Schinas G. Papageorgiou D. Rapid molecular diagnostics in vulvovaginal candidosis. Diagnostics 2024 14 20 2313 10.3390/diagnostics14202313 39451635
    [Google Scholar]
  28. Satora M. Grunwald A. Zaremba B. Treatment of Vulvovaginal Candidiasis - An overview of guidelines and the latest treatment methods. J. Clin. Med. 2023 12 16 5376 10.3390/jcm12165376 37629418
    [Google Scholar]
  29. Donders G. Sziller I.O. Paavonen J. Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Front. Cell. Infect. Microbiol. 2022 12 934353 10.3389/fcimb.2022.934353 36159646
    [Google Scholar]
  30. Sharma M. Chakrabarti A. Candidiasis and other emerging yeasts. Curr. Fungal Infect. Rep. 2023 17 1 15 24 10.1007/s12281‑023‑00455‑3 36741271
    [Google Scholar]
  31. Chauhan V. Kumar A. Tripathi S. An update on the pathogenesis and ethnopharmacological therapeutic approaches of vulvovaginal candidiasis. Discover Public Health 2024 21 1 195 10.1186/s12982‑024‑00274‑y
    [Google Scholar]
  32. Talapko J. Juzbašić M. Matijević T. Candida albicans - The virulence factors and clinical manifestations of infection. J. Fungi 2021 7 2 79 10.3390/jof7020079 33499276
    [Google Scholar]
  33. Gaziano R. Sabbatini S. Monari C. The interplay between Candida albicans, vaginal mucosa, host Immunity and resident microbiota in health and disease: An overview and future perspectives. Microorganisms 2023 11 5 1211 10.3390/microorganisms11051211 37317186
    [Google Scholar]
  34. Mogavero S. Höfs S. Lauer A.N. Candidalysin is the hemolytic factor of Candida albicans. Toxins 2022 14 12 874 10.3390/toxins14120874 36548771
    [Google Scholar]
  35. Cavalheiro M. Teixeira M.C. Candida biofilms: Threats, challenges and promising strategies. Front. Med. 2018 5 28 10.3389/fmed.2018.00028 29487851
    [Google Scholar]
  36. Tsui C. Kong E.F. Jabra-Rizk M.A. Pathogenesis of Candida albicans biofilm. Pathog. Dis. 2016 74 4 ftw018 10.1093/femspd/ftw018 26960943
    [Google Scholar]
  37. Alim D. Sircaik S. Panwar S.L. The significance of lipids to biofilm formation in Candida albicans: An emerging perspective. J. Fungi 2018 4 4 140 10.3390/jof4040140 30567300
    [Google Scholar]
  38. Ponde N.O. Lortal L. Ramage G. Naglik J.R. Richardson J.P. Candida albicans biofilms and polymicrobial interactions. Crit. Rev. Microbiol. 2021 47 1 91 111 10.1080/1040841X.2020.1843400 33482069
    [Google Scholar]
  39. Mallick E.M. Bergeron A.C. Jones S.K. Phenotypic plasticity regulates Candida albicans interactions and virulence in the vertebrate host. Front. Microbiol. 2016 7 780 10.3389/fmicb.2016.00780 27303374
    [Google Scholar]
  40. Malinovská Z. Čonková E. Váczi P. Biofilm formation in medically important Candida species. J. Fungi 2023 9 10 955 10.3390/jof9100955 37888211
    [Google Scholar]
  41. Fung S. Shirley M. Oteseconazole in recurrent vulvovaginal candidiasis: A profile of its use. Drugs Ther. Perspect. 2023 39 8 263 269 10.1007/s40267‑023‑01008‑x
    [Google Scholar]
  42. Jallow S. Govender N.P. Ibrexafungerp: A first-in-class oral triterpenoid glucan synthase inhibitor. J. Fungi 2021 7 3 163 10.3390/jof7030163 33668824
    [Google Scholar]
  43. Ngece K. Ntondini T.L. Khwaza V. Paca A.M. Aderibigbe B.A. Polyene-based derivatives with antifungal activities. Pharmaceutics 2024 16 8 1065 10.3390/pharmaceutics16081065 39204411
    [Google Scholar]
  44. Szymański M. Chmielewska S. Czyżewska U. Malinowska M. Tylicki A. Echinocandins – Structure, mechanism of action and use in antifungal therapy. J. Enzyme Inhib. Med. Chem. 2022 37 1 876 894 10.1080/14756366.2022.2050224 35296203
    [Google Scholar]
  45. Li Y. Yang J. Li X. The effect of Ginkgolide B combined with fluconazole against drug-resistant Candida albicans based on common resistance mechanisms. Int. J. Antimicrob. Agents 2020 56 2 106030 10.1016/j.ijantimicag.2020.106030 32454072
    [Google Scholar]
  46. Reginatto P. Bergamo V.Z. Berlitz S.J. Guerreiro I.C.K. de Andrade S.F. Fuentefria A.M. Rational selection of antifungal drugs to propose a new formulation strategy to control Candida biofilm formation on venous catheters. Braz. J. Microbiol. 2020 51 3 1037 1049 10.1007/s42770‑020‑00242‑z 32077074
    [Google Scholar]
  47. Felix T.C. de Brito Röder D.V.D. dos Santos Pedroso R. Alternative and complementary therapies for vulvovaginal candidiasis. Folia Microbiol. (Praha) 2019 64 2 133 141 10.1007/s12223‑018‑0652‑x 30269301
    [Google Scholar]
  48. Khan M.S.A. Ahmad I. Herbal medicine: Current trends and future prospects. New look to phytomedicine. Chapter 1 Elsevier 2019 3 13 10.1016/B978‑0‑12‑814619‑4.00001‑X
    [Google Scholar]
  49. Krzepiłko A. Kordowska-Wiater M. Sosnowska B. Pytka M. The effect of plant extracts on microorganisms. Poland University of Life Sciences in Lublin 2020 10.24326/mon.2020.4
    [Google Scholar]
  50. Romero-Cerecero O. Islas-Garduño A.L. Zamilpa A. Tortoriello J. Effectiveness of Ageratina pichinchensis extract in patients with vulvovaginal candidiasis. A randomized, double-blind and controlled pilot study. Phytother. Res. 2017 31 6 885 890 10.1002/ptr.5802 28299831
    [Google Scholar]
  51. Saffari E. Mohammad-Alizadeh-Charandabi S. Adibpour M. Mirghafourvand M. Javadzadeh Y. Comparing the effects of Calendula officinalis and clotrimazole on vaginal Candidiasis: A randomized controlled trial. Women Health 2017 57 10 1145 1160 10.1080/03630242.2016.1263272 27880086
    [Google Scholar]
  52. Ebrahimy F. Dolatian M. Moatar F. Alavi Majd H. Comparison of the therapeutic effects of Garcin® and fluconazole on Candida vaginitis. Singapore Med. J. 2015 56 10 567 572 10.11622/smedj.2015153 26512149
    [Google Scholar]
  53. Imhof M. Lipovac M. Kurz C. Barta J. Verhoeven H.C. Huber J.C. Propolis solution for the treatment of chronic vaginitis. Int. J. Gynaecol. Obstet. 2005 89 2 127 132 10.1016/j.ijgo.2005.01.033 15847875
    [Google Scholar]
  54. Feldman M. Sionov R.V. Mechoulam R. Steinberg D. Anti-biofilm activity of cannabidiol against Candida albicans. Microorganisms 2021 9 2 441 10.3390/microorganisms9020441 33672633
    [Google Scholar]
  55. Singh V. Vihal S. Rana R. Rathore C. Nanocarriers for cannabinoid delivery: enhancing therapeutic potential. Recent Adv Drug Deliv Formul 2024 18 4 247 261 10.2174/0126673878300347240718100814 39356097
    [Google Scholar]
  56. Zida A. Bamba S. Yacouba A. Ouedraogo-Traore R. Guiguemdé R.T. Anti- Candida albicans natural products, sources of new antifungal drugs: A review. J. Mycol. Med. 2017 27 1 1 19 10.1016/j.mycmed.2016.10.002 27842800
    [Google Scholar]
  57. Andrade J.C. Kumar S. Kumar A. Černáková L. Rodrigues C.F. Application of probiotics in candidiasis management. Crit. Rev. Food Sci. Nutr. 2022 62 30 8249 8264 10.1080/10408398.2021.1926905 34024191
    [Google Scholar]
  58. Sharma M. Wasan A. Sharma R.K. Recent developments in probiotics: An emphasis on Bifidobacterium. Food Biosci. 2021 41 100993 10.1016/j.fbio.2021.100993
    [Google Scholar]
  59. Akinosoglou K. Schinas G. Polyzou E. Tsiakalos A. Donders G.G.G. Probiotics in the management of vulvovaginal candidosis. J. Clin. Med. 2024 13 17 5163 10.3390/jcm13175163 39274376
    [Google Scholar]
  60. Han Y. Ren Q. Does probiotics work for bacterial vaginosis and vulvovaginal candidiasis. Curr. Opin. Pharmacol. 2021 61 83 90 10.1016/j.coph.2021.09.004 34649216
    [Google Scholar]
  61. Raheem A. Liang L. Zhang G. Cui S. Modulatory effects of probiotics during pathogenic infections with emphasis on immune regulation. Front. Immunol. 2021 12 616713 10.3389/fimmu.2021.616713 33897683
    [Google Scholar]
  62. Ribeiro F.C. Rossoni R.D. Barros P.P. Action mechanisms of probiotics on Candida spp. and candidiasis prevention: An update. J. Appl. Microbiol. 2020 129 2 175 185 10.1111/jam.14511 31705713
    [Google Scholar]
  63. Borges S. Silva J. Teixeira P. The role of lactobacilli and probiotics in maintaining vaginal health. Arch. Gynecol. Obstet. 2014 289 3 479 489 10.1007/s00404‑013‑3064‑9 24170161
    [Google Scholar]
  64. Chee W.J.Y. Chew S.Y. Than L.T.L. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb. Cell Fact. 2020 19 1 203 10.1186/s12934‑020‑01464‑4 33160356
    [Google Scholar]
  65. Fidel P.L. Cutler J.E. Prospects for development of a vaccine to prevent and control vaginal candidiasis. Curr. Infect. Dis. Rep. 2011 13 1 102 107 10.1007/s11908‑010‑0143‑y 21308461
    [Google Scholar]
  66. Pietrella D. Rachini A. Torosantucci A. A β-glucan-conjugate vaccine and anti-β-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 2010 28 7 1717 1725 10.1016/j.vaccine.2009.12.021 20038431
    [Google Scholar]
  67. De Bernardis F. Amacker M. Arancia S. A virosomal vaccine against candidal vaginitis: Immunogenicity, efficacy and safety profile in animal models. Vaccine 2012 30 30 4490 4498 10.1016/j.vaccine.2012.04.069 22561143
    [Google Scholar]
  68. Vanić Ž. Škalko-Basnet N. Nanopharmaceuticals for improved topical vaginal therapy: Can they deliver? Eur. J. Pharm. Sci. 2013 50 1 29 41 10.1016/j.ejps.2013.04.035 23684936
    [Google Scholar]
  69. Kaur I.P. Kakkar S. Topical delivery of antifungal agents. Expert Opin. Drug Deliv. 2010 7 11 1303 1327 10.1517/17425247.2010.525230 20961206
    [Google Scholar]
  70. Wall G. Lopez-Ribot J.L. Current antimycotics, new prospects and future approaches to antifungal therapy. Antibiotics 2020 9 8 445 10.3390/antibiotics9080445 32722455
    [Google Scholar]
  71. Laniado-Laborín R. Cabrales-Vargas M.N. Amphotericin B. Side effects and toxicity. Rev. Iberoam. Micol. 2009 26 4 223 227 10.1016/j.riam.2009.06.003 19836985
    [Google Scholar]
  72. Sobel J. Current treatment options for vulvovaginal candidiasis. Womens Health 2005 1 2 253 261 10.2217/17455057.1.2.253 19803842
    [Google Scholar]
  73. Rana P. Ghadlinge M. Roy V. Topical antifungal-corticosteroid fixed-drug combinations. Indian J. Pharmacol. 2021 53 1 82 84 10.4103/ijp.ijp_930_20 33976006
    [Google Scholar]
  74. Sobel J. Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Patient Prefer. Adherence 2013 8 31 34 10.2147/PPA.S38984 24368881
    [Google Scholar]
  75. Kyle J.A. The fungus among us: An antifungal review. US Pharm. 2010 35 8 44 56
    [Google Scholar]
  76. Palmeira-de-Oliveira R. Palmeira-de-Oliveira A. Martinez-de-Oliveira J. New strategies for local treatment of vaginal infections. Adv. Drug Deliv. Rev. 2015 92 105 122 10.1016/j.addr.2015.06.008 26144995
    [Google Scholar]
  77. Conte J. Parize A.L. Caon T. Advanced solid formulations for vulvovaginal candidiasis. Pharm. Res. 2023 40 2 593 610 10.1007/s11095‑022‑03441‑5 36451068
    [Google Scholar]
  78. Gupta S. Gabrani R. Ali J. Dang S. Exploring novel approaches to vaginal drug delivery. Recent Pat. Drug Deliv. Formul. 2011 5 2 82 94 10.2174/187221111795471418 21413924
    [Google Scholar]
  79. Osmałek T. Froelich A. Jadach B. Recent advances in polymer-based vaginal drug delivery systems. Pharmaceutics 2021 13 6 884 10.3390/pharmaceutics13060884 34203714
    [Google Scholar]
  80. Jarai B.M. Kolewe E.L. Stillman Z.S. Raman N. Polymeric nanoparticles. Nanoparticles for biomedical applications. Chapter 18 Elsevier 2020 303 324 10.1016/B978‑0‑12‑816662‑8.00018‑7
    [Google Scholar]
  81. das Neves J Nunes R, Machado A, Sarmento B. Polymer-based nanocarriers for vaginal drug delivery. Adv. Drug Deliv. Rev. 2015 92 53 70 10.1016/j.addr.2014.12.004 25550217
    [Google Scholar]
  82. Lalan M.S. Patel V.N. Misra A. Polymers in vaginal drug delivery: Recent advancements. In: Applications of polymers in drug delivery. Elsevier 2021 281 303 10.1016/B978‑0‑12‑819659‑5.00010‑0
    [Google Scholar]
  83. Desai N. Rana D. Salave S. Chitosan: A potential biopolymer in drug delivery and biomedical applications. Pharmaceutics 2023 15 4 1313 10.3390/pharmaceutics15041313 37111795
    [Google Scholar]
  84. de Araújo Pereira R.R. Bruschi M.L. Vaginal mucoadhesive drug delivery systems. Drug Dev. Ind. Pharm. 2012 38 6 643 652 10.3109/03639045.2011.623355 21999572
    [Google Scholar]
  85. Jafernik K. Ładniak A. Blicharska E. Chitosan-based nanoparticles as effective drug delivery systems - A review. Molecules 2023 28 4 1963 10.3390/molecules28041963 36838951
    [Google Scholar]
  86. da Silva J.T. Dantas de Sousa P.H. Costa A.F. Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model. Med. Mycol. 2023 61 11 myad113 10.1093/mmy/myad113 37947253
    [Google Scholar]
  87. Araújo D.E. de Oliveira A.A. Cabral M.S. Investigation of thiosemicarbazide free or within chitosan nanoparticles in a murine model of vulvovaginal candidiasis. Braz. J. Microbiol. 2020 51 4 1465 1473 10.1007/s42770‑020‑00326‑w 32638273
    [Google Scholar]
  88. Facchinatto W.M. Galante J. Mesquita L. Clotrimazole-loaded N-(2-hydroxy)-propyl-3-trimethylammonium, O-palmitoyl chitosan nanoparticles for topical treatment of vulvovaginal candidiasis. Acta Biomater. 2021 125 312 321 10.1016/j.actbio.2021.02.029 33639312
    [Google Scholar]
  89. Jøraholmen M.W. Vanić Ž. Tho I. Škalko-Basnet N. Chitosan-coated liposomes for topical vaginal therapy: Assuring localized drug effect. Int. J. Pharm. 2014 472 1-2 94 101 10.1016/j.ijpharm.2014.06.016 24928137
    [Google Scholar]
  90. Sun B. Zhang M. Shen J. He Z. Fatehi P. Ni Y. Applications of cellulose-based materials in sustained drug delivery systems. Curr. Med. Chem. 2019 26 14 2485 2501 10.2174/0929867324666170705143308 28685683
    [Google Scholar]
  91. Sapa H. Nair S.C. Sabitha M. Cellulose and cellulose derivatives in drug delivery. Natural Biopolymers in Drug Delivery and Tissue Engineering. Elsevier 2023 77 100 10.1016/B978‑0‑323‑98827‑8.00023‑0
    [Google Scholar]
  92. del Rocío Lara-Sánchez M. Ganem-Rondero A. Nava-Arzaluz M.G. Microbicidal polymer nanoparticles containing clotrimazole for treatment of vulvovaginal candidiasis. AAPS PharmSciTech 2024 25 7 197 10.1208/s12249‑024‑02914‑7 39174702
    [Google Scholar]
  93. Calvo N.L. Svetaz L.A. Alvarez V.A. Quiroga A.D. Lamas M.C. Leonardi D. Chitosan-hydroxypropyl methylcellulose tioconazole films: A promising alternative dosage form for the treatment of vaginal candidiasis. Int. J. Pharm. 2019 556 181 191 10.1016/j.ijpharm.2018.12.011 30553009
    [Google Scholar]
  94. Conte J. Saatkamp R.H. Sanches M.P. Development of biopolymer films loaded with fluconazole and thymol for resistant vaginal candidiasis. Int. J. Biol. Macromol. 2024 275 Pt 2 133356 10.1016/j.ijbiomac.2024.133356 38945715
    [Google Scholar]
  95. Kim J.T. Lee D-Y. Kim Y-H. Lee I-K. Song Y-S. Effect of pH on swelling property of hyaluronic acid hydrogels for smart drug delivery systems. J Sensor Sci Technol 2012 21 4 256 262 10.5369/JSST.2012.21.4.256
    [Google Scholar]
  96. Tripodo G Trapani A Torre ML Giammona G Trapani G Mandracchia D Hyaluronic acid and its derivatives in drug delivery and imaging: Recent advances and challenges. Eur J Pharm Biopharm 2015 97 Pt B 400 16 10.1016/j.ejpb.2015.03.032 266145592
    [Google Scholar]
  97. Teixeira A.D.R. Quaresma A.D.V. Branquinho R.T. Miconazole-loaded nanoparticles coated with hyaluronic acid to treat vulvovaginal candidiasis. Eur. J. Pharm. Sci. 2023 188 106508 10.1016/j.ejps.2023.106508 37379779
    [Google Scholar]
  98. Parolin C. Abruzzo A. Giordani B. Anti-Candida activity of hyaluronic acid combined with Lactobacillus crispatus lyophilised supernatant: A new antifungal strategy. Antibiotics 2021 10 6 628 10.3390/antibiotics10060628 34070335
    [Google Scholar]
  99. Amorós M. Mora Palma J.C. Esteve M. Experience with a non-hormonal Centella asiatica, hyaluronic acid and prebiotic-based vaginal gel in women with recurrent vulvovaginal candidiasis: Case studies. Clin. Med. Insights Case Rep. 2023 16 11795476231161170 10.1177/11795476231161170 36950702
    [Google Scholar]
  100. Dalei G. Das S. Polyacrylic acid-based drug delivery systems: A comprehensive review on the state-of-art. J. Drug Deliv. Sci. Technol. 2022 78 103988 10.1016/j.jddst.2022.103988
    [Google Scholar]
  101. Deshkar S.S. Shirolkar S.V. Patil A.T. Vaginal bioadhesive drug delivery systems and their applications. Bioadhesives in Drug Delivery. Wiley 2020 303 324 10.1002/9781119640240.ch11
    [Google Scholar]
  102. Campos L.M. de Oliveira Lemos A.S. de Lima Paula P. Exploring the antifungal potential of Annona muricata leaf extract-loaded hydrogel in treating vulvovaginal candidiasis. Colloids Surf. B Biointerfaces 2024 238 113919 10.1016/j.colsurfb.2024.113919 38663311
    [Google Scholar]
  103. D’souza A.A. Shegokar R. Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications. Expert Opin. Drug Deliv. 2016 13 9 1257 1275 10.1080/17425247.2016.1182485 27116988
    [Google Scholar]
  104. Verma A. PEG based suppositories bearing anti-tubercular drugs: Effect of drug loading on release and physical properties. Lat. Am. J. Pharm. 2021 40 12 2841 2847
    [Google Scholar]
  105. Pan H. Xu J. Wang R. Cheng M. Wang Y. Song B. Development of ROS-sensitive capofungin hydrogel by crosslinking chitosan with four-arm polyethylene glycol derivative for treatment of vulvovaginal candidiasis. Int. J. Biol. Macromol. 2024 279 Pt 1 135157 10.1016/j.ijbiomac.2024.135157 39214224
    [Google Scholar]
  106. Abd Ellah N.H. Shaltout A.S. Abd El Aziz S.M.M. Vaginal suppositories of cumin seeds essential oil for treatment of vaginal candidiasis: Formulation, in vitro, in vivo and clinical evaluation. Eur. J. Pharm. Sci. 2021 157 105602 10.1016/j.ejps.2020.105602 33086117
    [Google Scholar]
  107. Zarrintaj P. Ramsey J.D. Samadi A. Poloxamer: A versatile tri-block copolymer for biomedical applications. Acta Biomater. 2020 110 37 67 10.1016/j.actbio.2020.04.028 32417265
    [Google Scholar]
  108. Mfoafo K. Omidi Y. Omidian H. Thermoresponsive mucoadhesive hybrid gels in advanced drug delivery systems. Int. J. Pharm. 2023 636 122799 10.1016/j.ijpharm.2023.122799 36914019
    [Google Scholar]
  109. Dantas-Medeiros R. Marena G.D. Araújo V.H.S. A new hydrogel containing a proanthocyanidin polymer-rich extract of Commiphora leptophloeos for treating vulvovaginal candidiasis: Preclinical results using the alternative model of Galleria mellonella. J. Drug Deliv. Sci. Technol. 2023 85 104531 10.1016/j.jddst.2023.104531
    [Google Scholar]
  110. Goodwin M.J. Musa O.M. Berry D.J. Steed J.W. Small-molecule povidone analogues in coamorphous pharmaceutical phases. Cryst. Growth Des. 2018 18 2 701 709 10.1021/acs.cgd.7b01062
    [Google Scholar]
  111. Pires P.C. Mascarenhas-Melo F. Pedrosa K. Polymer-based biomaterials for pharmaceutical and biomedical applications: A focus on topical drug administration. Eur. Polym. J. 2023 187 111868 10.1016/j.eurpolymj.2023.111868
    [Google Scholar]
  112. Afrashi M. Nasari M. Semnani D. Dehghan P. Maheronnaghsh M. Comparison of the antifungal activity of fluconazole- and ketoconazole-loaded PCL/PVP nanofibrous mat. Bull. Mater. Sci. 2021 44 2 166 10.1007/s12034‑021‑02456‑9
    [Google Scholar]
  113. Shrestha H. Bala R. Arora S. Lipid‐based drug delivery systems. J. Pharm. 2014 2014 1 801820 26556202
    [Google Scholar]
  114. Gbian D.L. Omri A. Lipid-based drug delivery systems for diseases managements. Biomedicines 2022 10 9 2137 10.3390/biomedicines10092137 36140237
    [Google Scholar]
  115. Abdellatif M.M. Khalil I.A. Elakkad Y.E. Eliwa H.A. Samir T. Al-Mokaddem A.K. Formulation and characterization of sertaconazole nitrate mucoadhesive liposomes for vaginal candidiasis. Int. J. Nanomedicine 2020 15 4079 4090 10.2147/IJN.S250960 32606665
    [Google Scholar]
  116. Giordani B. Basnet P. Mishchenko E. Luppi B. Škalko-Basnet N. Utilizing liposomal quercetin and gallic acid in localized treatment of vaginal candida infections. Pharmaceutics 2019 12 1 9 10.3390/pharmaceutics12010009 31861805
    [Google Scholar]
  117. Khan M.A. Mousa A.M. Alradhi A.E. Allemailem K. Efficacy of lipid nanoparticles-based vaccine to protect against vulvovaginal candidiasis (VVC): Implications for women’s reproductive health. Life Sci. 2025 361 123312 10.1016/j.lfs.2024.123312 39674269
    [Google Scholar]
  118. Muller H. 20 years of lipid nanoparticles (SLN & NLC): Present state of development & industrial applications. Curr. Drug Discov. Technol. 2011 8 3 207 227 10.2174/157016311796799062 21291409
    [Google Scholar]
  119. Yih T.C. Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J. Cell. Biochem. 2006 97 6 1184 1190 10.1002/jcb.20796 16440317
    [Google Scholar]
  120. Firdaus S. Hassan N. Mirza M.A. FbD directed fabrication and investigation of luliconazole based SLN gel for the amelioration of candidal vulvovaginitis: A 2 T (thermosensitive & transvaginal) approach. Saudi J. Biol. Sci. 2021 28 1 317 326 10.1016/j.sjbs.2020.10.005 33424312
    [Google Scholar]
  121. Cassano R. Ferrarelli T. Mauro M.V. Cavalcanti P. Picci N. Trombino S. Preparation, characterization and in vitro activities evaluation of solid lipid nanoparticles based on PEG-40 stearate for antifungal drugs vaginal delivery. Drug Deliv. 2016 23 3 1037 1046 10.3109/10717544.2014.932862 25005582
    [Google Scholar]
  122. Basu B. Dutta A. Parihar A. Prajapati B. Majumder R. Ethosomes: A lipid-based drug delivery system. In: Lipid-Based Drug Delivery Systems. Jenny Stanford Publishing 2023 223 297 10.1201/9781003459811‑8
    [Google Scholar]
  123. Paiva-Santos A.C. Silva A.L. Guerra C. Ethosomes as nanocarriers for the development of skin delivery formulations. Pharm. Res. 2021 38 6 947 970 10.1007/s11095‑021‑03053‑5 34036520
    [Google Scholar]
  124. Singh A. Agarwal S. Sourirajan A. Butea monosperma seed oil loaded ethosomal vesicular carrier and its hydrogel for vaginal candidiasis: QbD based development, in vitro and in vivo evaluation. Bionanoscience 2024 14 3 3011 3034 10.1007/s12668‑024‑01575‑x
    [Google Scholar]
  125. El-Hammadi M. Arias J. Nano-sized platforms for vaginal drug delivery. Curr. Pharm. Des. 2015 21 12 1633 1644 10.2174/1381612820666141029150427 25354177
    [Google Scholar]
  126. Song R. Yan F. Cheng M. Ultrasound-assisted preparation of exopolysaccharide/nystatin nanoemulsion for treatment of vulvovaginal candidiasis. Int. J. Nanomedicine 2020 15 2027 2044 10.2147/IJN.S241134 32273700
    [Google Scholar]
  127. Gündel S.S. de Godoi S.N. Santos R.C.V. In vivo antifungal activity of nanoemulsions containing eucalyptus or lemongrass essential oils in murine model of vulvovaginal candidiasis. J. Drug Deliv. Sci. Technol. 2020 57 101762 10.1016/j.jddst.2020.101762
    [Google Scholar]
  128. Talaat S.M. Elnaggar Y.S.R. Abdalla O.Y. Lecithin microemulsion lipogels versus conventional gels for skin targeting of terconazole: In vitro, ex vivo and in vivo investigation. AAPS PharmSciTech 2019 20 4 161 10.1208/s12249‑019‑1374‑3 30969396
    [Google Scholar]
  129. Dholakia M.S. Patel D. Patel K.A. Development of novel women’s friendly antifungal microemulsion loaded gel for vulvovaginal infections. Drug Deliv. Lett. 2024 14 4 308 319 10.2174/0122103031304658240627063415
    [Google Scholar]
  130. Gaspar de Toledo L. dos Santos Ramos M.A. Bento da Silva P. Improved in vitro and in vivo anti-Candida albicans activity of Cymbopogon nardus essential oil by its incorporation into a microemulsion system. Int. J. Nanomedicine 2020 15 10481 10497 10.2147/IJN.S275258 33402821
    [Google Scholar]
  131. Ahmad M.Z. Ahmad J. Alasmary M.Y. Nanoemulgel as an approach to improve the biopharmaceutical performance of lipophilic drugs: Contemporary research and application. J. Drug Deliv. Sci. Technol. 2022 72 103420 10.1016/j.jddst.2022.103420
    [Google Scholar]
  132. Tayah D.Y. Eid A.M. Development of miconazole nitrate nanoparticles loaded in nanoemulgel to improve its antifungal activity. Saudi Pharm. J. 2023 31 4 526 534 10.1016/j.jsps.2023.02.005 37063448
    [Google Scholar]
  133. Aleanizy F.S. Taha E.I. Salem-Bekhit M.M. Formulation and in vitro and in vivo evaluation of surfactant-stabilized mucoadhesive nanogels for vaginal delivery of fluconazole. Drug Dev. Ind. Pharm. 2021 47 12 1935 1942 10.1080/03639045.2022.2070760 35537065
    [Google Scholar]
  134. Yuan H. Wang L.L. Du Y.Z. You J. Hu F.Q. Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf. B Biointerfaces 2007 60 2 174 179 10.1016/j.colsurfb.2007.06.011 17656075
    [Google Scholar]
  135. Saupe A. Wissing S.A. Lenk A. Schmidt C. Müller R.H. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) -- structural investigations on two different carrier systems. Biomed. Mater. Eng. 2005 15 5 393 402 16179760
    [Google Scholar]
  136. Sato M.R. Oshiro-Junior J.A. Rodero C.F. Photodynamic therapy-mediated hypericin-loaded nanostructured lipid carriers against vulvovaginal candidiasis. J. Mycol. Med. 2022 32 4 101296 10.1016/j.mycmed.2022.101296 35660541
    [Google Scholar]
  137. Sato M.R. Oshiro-Junior J.A. Rodero C.F. Enhancing antifungal treatment of Candida albicans with hypericin-loaded nanostructured lipid carriers in hydrogels: characterization, in vitrom and in vivo photodynamic evaluation. Pharmaceuticals 2023 16 8 1094 10.3390/ph16081094 37631009
    [Google Scholar]
  138. Kanojiya P.S. Wadetwar R.N. Atole P.G. Sustained delivery of statistically optimized transfersomal gel of miconazole nitrate for vaginal candidiasis. J. Dispers. Sci. Technol. 2023 46 2 333 350 10.1080/01932691.2023.2289621
    [Google Scholar]
  139. De Matteis V. Exposure to inorganic nanoparticles: routes of entry, immune response, biodistribution and in vitro/in vivo toxicity evaluation. Toxics 2017 5 4 29 10.3390/toxics5040029 29051461
    [Google Scholar]
  140. Rosi N.L. Mirkin C.A. Nanostructures in Biodiagnostics. Chem. Rev. 2005 105 4 1547 1562 10.1021/cr030067f 15826019
    [Google Scholar]
  141. Wang Y.X.J. Hussain S.M. Krestin G.P. Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur. Radiol. 2001 11 11 2319 2331 10.1007/s003300100908 11702180
    [Google Scholar]
  142. Rousserie G. Sukhanova A. Even-Desrumeaux K. Semiconductor quantum dots for multiplexed bio-detection on solid-state microarrays. Crit. Rev. Oncol. Hematol. 2010 74 1 1 15 10.1016/j.critrevonc.2009.04.006 19467882
    [Google Scholar]
  143. Jain P.K. El-Sayed I.H. El-Sayed M.A. Au nanoparticles target cancer. Nano Today 2007 2 1 18 29 10.1016/S1748‑0132(07)70016‑6
    [Google Scholar]
  144. Brongersma M.L. Nanoshells: gifts in a gold wrapper. Nat. Mater. 2003 2 5 296 297 10.1038/nmat891 12728232
    [Google Scholar]
  145. Hashemi H. Varshosaz J. Fazeli H. Rapid differential diagnosis of vaginal infections using gold nanoparticles coated with specific antibodies. Med. Microbiol. Immunol. 2019 208 6 773 780 10.1007/s00430‑019‑00622‑9 31183547
    [Google Scholar]
  146. Yu T. Hou J. Hafeez F. Fungus-mediated biosynthesis of gold nanoparticles with synergistic antifungal activity against multidrug-resistant Candida albicans. Nano Today 2024 59 102486 10.1016/j.nantod.2024.102486
    [Google Scholar]
  147. Wang J. Su L. Li Y. Liu Y. Xie L. Nanoscale fluconazole-constructed metal-organic frameworks with smart drug release for eradication of Candida biofilms in vulvovaginitis infection. Colloids Surf. B Biointerfaces 2025 245 114238 10.1016/j.colsurfb.2024.114238 39270401
    [Google Scholar]
  148. Clack K. Sallam M. Muyldermans S. Sambasivam P. Nguyen C.M. Nguyen N.T. Instant Candida albicans detection using ultra-stable aptamer conjugated gold nanoparticles. Micromachines 2024 15 2 216 10.3390/mi15020216 38398945
    [Google Scholar]
  149. Clack K. Sallam M. Matheson C. Muyldermans S. Nguyen N.T. Towards a wearable feminine hygiene platform for detection of invasive fungal pathogens via gold nanoparticle aggregation. Micromachines 2024 15 7 899 10.3390/mi15070899 39064410
    [Google Scholar]
  150. Waghule T. Singhvi G. Dubey S.K. Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomed. Pharmacother. 2019 109 1249 1258 10.1016/j.biopha.2018.10.078 30551375
    [Google Scholar]
  151. Quinn H.L. Kearney M.C. Courtenay A.J. McCrudden M.T.C. Donnelly R.F. The role of microneedles for drug and vaccine delivery. Expert Opin. Drug Deliv. 2014 11 11 1769 1780 10.1517/17425247.2014.938635 25020088
    [Google Scholar]
  152. Aldawood F.K. Andar A. Desai S. A comprehensive review of microneedles: Types, materials, processes, characterizations and applications. Polymers 2021 13 16 2815 10.3390/polym13162815 34451353
    [Google Scholar]
  153. Kristina Enggi C. Sulistiawati S. Stephanie S. Development of probiotic loaded multilayer microcapsules incorporated into dissolving microneedles for potential improvement treatment of vulvovaginal candidiasis: A proof of concept study. J. Colloid Interface Sci. 2023 648 203 219 10.1016/j.jcis.2023.05.165 37301145
    [Google Scholar]
  154. Aziz A.Y.R. Mahfufah U. Syahirah N.A. Dual delivery systems combining nanocrystals and dissolving microneedles for improved local vaginal delivery of fluconazole. Drug Deliv. Transl. Res. 2024 14 6 1678 1692 10.1007/s13346‑023‑01483‑9 38036850
    [Google Scholar]
  155. Dolci L.S. Albertini B. Di Filippo M.F. Bonvicini F. Passerini N. Panzavolta S. Development and in vitro evaluation of mucoadhesive gelatin films for the vaginal delivery of econazole. Int. J. Pharm. 2020 591 119979 10.1016/j.ijpharm.2020.119979 33068694
    [Google Scholar]
  156. Bassi P. Kaur G. Bioadhesive vaginal drug delivery of nystatin using a derivatized polymer: Development and characterization. Eur. J. Pharm. Biopharm. 2015 96 173 184 10.1016/j.ejpb.2015.07.018 26235393
    [Google Scholar]
  157. Mandlik P.L. Lad P.R. Pandit A.P. Fluconazole microsponges loaded bioadhesive vaginal film to treat vulvovaginal candidiasiss. J. Pharm. Innov. 2024 19 2 12 10.1007/s12247‑024‑09822‑0
    [Google Scholar]
  158. Martins F. Morgado D.L. Sarmento B. de Camargo E.R. das Neves J. Chitosan-based sponges containing clotrimazole for the topical management of vulvovaginal candidiasis. Int. J. Pharm. 2023 647 123508 10.1016/j.ijpharm.2023.123508 37832705
    [Google Scholar]
  159. Rossi S. Marciello M. Ferrari F. Development of sponge-like dressings for mucosal/transmucosal drug delivery into vaginal cavity. Pharm. Dev. Technol. 2012 17 2 219 226 10.3109/10837450.2010.531736 21077750
    [Google Scholar]
  160. El-Salamouni N.S. Yakout M.A. Labib G.S. Farid R.M. Preparation and evaluation of vaginal suppo-sponges loaded with benzydamine, in-vitro/in-vivo study. Pharm. Dev. Technol. 2024 29 2 86 97 10.1080/10837450.2024.2306803 38243554
    [Google Scholar]
  161. Shaker D.S. Ismail S. Hamed S. El-Shishtawy E.M. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy. J. Drug Deliv. Sci. Technol. 2018 48 274 287 10.1016/j.jddst.2018.09.011
    [Google Scholar]
  162. Sofi H.S. Ashraf R. Khan A.H. Beigh M.A. Majeed S. Sheikh F.A. Reconstructing nanofibers from natural polymers using surface functionalization approaches for applications in tissue engineering, drug delivery and biosensing devices. Mater. Sci. Eng. C 2019 94 1102 1124 10.1016/j.msec.2018.10.069 30423692
    [Google Scholar]
  163. Vidyadhari A. Singh N. Singh A.K. Investigation of luliconazole-loaded mucoadhesive electrospun nanofibers for anticandidal activity in the management of vaginal candidiasis. ACS Omega 2023 8 45 42102 42113 10.1021/acsomega.3c02141 38024758
    [Google Scholar]
  164. Pillay V. Dott C. Choonara Y.E. A review of the effect of processing variables on the fabrication of electrospun nanofibers for drug delivery applications. J. Nanomater. 2013 2013 1 789289 10.1155/2013/789289
    [Google Scholar]
  165. Omer S. Forgách L. Zelkó R. Sebe I. Scale-up of electrospinning: Market overview of products and devices for pharmaceutical and biomedical purposes. Pharmaceutics 2021 13 2 286 10.3390/pharmaceutics13020286 33671624
    [Google Scholar]
  166. Souza R.O. Henrique de Lima T. Oréfice R.L. Amphotericin B-loaded poly (lactic-co-glycolic acid) nanofibers: An alternative therapy scheme for local treatment of vulvovaginal candidiasis. J. Pharm. Sci. 2018 107 10 2674 2685 10.1016/j.xphs.2018.06.017 29940181
    [Google Scholar]
  167. Tuğcu-Demiröz F. Saar S. Kara A.A. Yıldız A. Tunçel E. Acartürk F. Development and characterization of chitosan nanoparticles loaded nanofiber hybrid system for vaginal controlled release of benzydamine. Eur. J. Pharm. Sci. 2021 161 105801 10.1016/j.ejps.2021.105801 33691155
    [Google Scholar]
  168. Deshkar S.S. Palve V.K. Formulation and development of thermosensitive cyclodextrin-based in situ gel of voriconazole for vaginal delivery. J. Drug Deliv. Sci. Technol. 2019 49 277 285 10.1016/j.jddst.2018.11.023
    [Google Scholar]
  169. Alwan O.M. Jaafar I.S. Development of synergistic antifungal in situ gel of miconazole nitrate loaded microemulsion as a novel approach to treat vaginal candidiasis. Sci. Rep. 2024 14 1 23168 10.1038/s41598‑024‑74021‑3 39369062
    [Google Scholar]
  170. Zhang Y. Chen X. Dai J. Wang C. Ma S. Du L. Effects of intravaginal curcumin gels combined with electroporation on vulvovaginal candidiasis. J Tradit Chin Med Sci 2024 12 1 79 85 10.1016/j.jtcms.2024.11.002
    [Google Scholar]
  171. Mork S. Johannessen M. Škalko-Basnet N. Jøraholmen M.W. Chitosan and liposomal delivery systems for epicatechin or propyl gallate targeting localized treatment of vulvovaginal candidiasis. Int. J. Pharm. 2024 662 124489 10.1016/j.ijpharm.2024.124489 39032871
    [Google Scholar]
  172. Menon S. Vartak R. Patel K. Billack B. Evaluation of the antifungal activity of an ebselen-loaded nanoemulsion in a mouse model of vulvovaginal candidiasis. Nanomedicine 2021 37 102428 10.1016/j.nano.2021.102428 34217850
    [Google Scholar]
  173. Riaz A. Hendricks S. Elbrink K. Preparation and characterization of nanostructured lipid carriers for improved topical drug delivery: evaluation in cutaneous leishmaniasis and vaginal candidiasis animal models. AAPS PharmSciTech 2020 21 5 185 10.1208/s12249‑020‑01717‑w
    [Google Scholar]
  174. Suaifan G.A.R.Y. Shehadeh M.B. Darwish R. Magnetic nanobead paper-based biosensors for colorimetric detection of Candida albicans. ACS Omega 2024 9 42 43005 43015 10.1021/acsomega.4c05941 39464470
    [Google Scholar]
  175. Maciel AAM Cunha FA Freire TM Development and evaluation of an anti-candida cream based on silver nanoparticles. 2023 3 Biotech 352 10.1007/s13205‑023‑03776‑9
    [Google Scholar]
  176. Li X. Xu Y. Ouyang D. Copper- and iodine-doped nanozymes with simulated enzyme activity and efficient antifungal activity against Candida albicans. Biochem. Eng. J. 2023 191 108791 10.1016/j.bej.2022.108791
    [Google Scholar]
  177. Tomarchio E.G. Zagni C. Dattilo S. Advanced cyclodextrin-based multiloaded hydrogels for targeted drug delivery in the fight against vaginal fungal infections. Carbohydr. Polym. 2025 356 123412 10.1016/j.carbpol.2025.123412 40049981
    [Google Scholar]
  178. Alloush T. Yurtdaş Kırımlıoğlu G. Development of vaginal in situ gel containing ISN/HP-β-CD inclusion complex for enhanced solubility and antifungal efficacy. Polymers 2025 17 4 514 10.3390/polym17040514 40006176
    [Google Scholar]
  179. Cevher E. Açma A. Sinani G. Aksu B. Zloh M. Mülazımoğlu L. Bioadhesive tablets containing cyclodextrin complex of itraconazole for the treatment of vaginal candidiasis. Int. J. Biol. Macromol. 2014 69 124 136 10.1016/j.ijbiomac.2014.05.033 24857873
    [Google Scholar]
  180. Vartak R. Patki M. Menon S. β-cyclodextrin polymer/] Soluplus® encapsulated Ebselen ternary complex (EβpolySol) as a potential therapy for vaginal candidiasis and pre-exposure prophylactic for HIV. Int. J. Pharm. 2020 589 119863 10.1016/j.ijpharm.2020.119863 32911046
    [Google Scholar]
  181. Permana A.D. Utomo E. Pratama M.R. Bioadhesive-thermosensitive in situ vaginal gel of the gel flake-solid dispersion of itraconazole for enhanced antifungal activity in the treatment of vaginal candidiasis. ACS Appl. Mater. Interfaces 2021 13 15 18128 18141 10.1021/acsami.1c03422 33840187
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128384805251014064906
Loading
Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy
Bentham Science Publishers ; https://doi.org/10.2174/0113816128384805251014064906
/content/journals/cpd/10.2174/0113816128384805251014064906
/content/journals/cpd/10.2174/0113816128384805251014064906
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Candida albicans ; Vulvovaginal candidiasis ; inorganic carriers ; antifungal therapy ; novel drug delivery systems ; polymers ; nanocarrier

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test